Literature DB >> 32632639

Combined PET/CT with thoracic contrast-enhanced CT in assessment of primary cardiac tumors in adult patients.

En-Tao Liu1, Tao-Tao Sun1, Hao-Jian Dong2, Si-Yun Wang1, Ze-Rui Chen3, Chao Liu4, Dan Shao1, Zhou-Yang Lian5, Qiu Xie6, Shu-Xia Wang7.   

Abstract

BACKGROUND: 18F-FDG PET/CT is a key molecular imaging modality to noninvasively assess and differentiate benign and malignant cardiac tumors. However, few benign cardiac tumors can be characterized by increased 18F-FDG uptake, which makes differential diagnosis difficult. This study sought to retrospectively evaluate whether combined 18F-FDG PET/CT with thoracic contrast-enhanced CT (CECT) helps in assessing primary cardiac tumors in adult patients, compared with CECT or PET/CT alone.
METHODS: Forty-six consecutive patients who were diagnosed as primary cardiac tumors were enrolled. All patients underwent 18F-FDG PET/CT followed by thoracic CECT before biopsy or surgery. Visual qualitative interpretation and quantitative analysis were performed, and diagnostic performance was evaluated.
RESULTS: More than half (16/29) of benign tumors exhibited with mild 18F-FDG uptake. There were significant differences in 18F-FDG uptake and the degree of absolute enhancement between benign and malignant tumors (P < 0.001). The combination of two modalities improved the specificity from 79 to 93%, the positive predictive value from 73 to 89%, and the accuracy of diagnosis from 85 to 93%. There were significant differences between PET/CT alone or thoracic CECT alone and combined modalities (P = 0.034 and P = 0.026, respectively). The combination with the optimal SUVmax cutoff value generated 94% sensitivity, 100% specificity, 97% negative predictive values, 100% positive predictive values, and 98% accuracy rates.
CONCLUSIONS: Combining 18F-FDG PET/C with thoracic CECT significantly improved specificity and accuracy compared to CECT or PET/CT alone in detecting tumors. This combination of diagnostic imaging is effective in differentiating malignant from benign masses.

Entities:  

Keywords:  18F-Fluorodeoxyglucose (18F-FDG); PET/CT; Primary cardiac tumors; Tomography, X-ray computed

Year:  2020        PMID: 32632639     DOI: 10.1186/s13550-020-00661-x

Source DB:  PubMed          Journal:  EJNMMI Res        ISSN: 2191-219X            Impact factor:   3.138


  2 in total

Review 1.  COVID-19 associated mucormycosis: evolving technologies for early and rapid diagnosis.

Authors:  Rachel Samson; Mahesh Dharne
Journal:  3 Biotech       Date:  2021-12-06       Impact factor: 2.893

2.  Diagnostic challenges in primary cardiac lymphoma, the opportunity of 18F-FDG PET/CT integrated with contrast-enhanced CT.

Authors:  Entao Liu; Jia Huang; Haojian Dong; Zerui Chen; Chao Liu; Qiu Xie; Weiping Xu; Shuxia Wang; Zaiyi Liu
Journal:  J Nucl Cardiol       Date:  2021-07-27       Impact factor: 3.872

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.